The Top Line cover image

Teva’s CEO shares ‘Pivot to Growth’ progress

The Top Line

00:00

Transforming to Biopharma: Teva's Growth Journey

This chapter outlines Teva's strategic transformation towards becoming a biopharma company, aiming for a $700 million cost reduction through modernization and resource reallocation. It highlights the company's recent growth after a five-year sales decline, with ambitious plans for innovative products and an emphasis on strengthening product pipelines. The speaker expresses optimism for the future, acknowledging the dedication of employees in this significant transition and the focus on sustained profitability and growth.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app